Study design and participants
Prostate Cancer
ONCOLOGY, PROSTATE CANCER, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
We did an open-label, dose-expansion, phase 1 study of a single priming dose of Eligible patients were men aged 18 years or older, with an Eastern Cooperative Oncology Group performance status of 0 or 1, who had histologically confirmed metastatic castration-resistant prostate cancer with progression at study entry, as per the Prostate Cancer Working Group 3 (PCWG3) criteria.The study protocol was approved by the ethics committees at the University of California San Francisco and regulatory authorities. All patients provided written informed consent, and the study adhered to the Declaration of Helsinki and Good Clinical Practice guidelines.